# A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

> **NCT00050778** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 334 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **BIOLOGICAL:** Interferon beta-1a
- **BIOLOGICAL:** Alemtuzumab 12 mg
- **BIOLOGICAL:** Alemtuzumab 24 mg

## Key facts

- **NCT ID:** NCT00050778
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2007-09
- **Final completion:** 2010-01
- **Target enrollment:** 334 (ACTUAL)
- **Last updated:** 2015-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050778, "A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00050778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*